About the job
Revolution Medicines is an innovative clinical-stage precision oncology firm dedicated to advancing cutting-edge targeted therapies aimed at disrupting critical targets in RAS-addicted cancers. Our extensive R&D pipeline features RAS(ON) Inhibitors intended to abrogate various oncogenic variants of RAS proteins, alongside RAS Companion Inhibitors for synergistic treatment approaches. Joining the Revolution Medicines team means becoming part of a passionate group committed to transforming the lives of patients battling cancers linked to mutations in the RAS signaling pathway.
The Opportunity:
As the Director of Molecular Pathology, you will play a pivotal role within our collaborative Translational Sciences Team, directly reporting to the Senior Director and Head of Translational Sciences in Translational Research. Your responsibilities will include:
Biomarker Strategy: Formulating and implementing molecular and digital pathology-driven biomarker strategies.
Integration of Advanced Modalities: Spearheading the use of molecular pathology and spatial technologies to enhance translational research and broader Biomedical Discovery Research (BDR) requirements.
Digital & Computational Pathology: Leading the deployment of whole-slide imaging, artificial intelligence/machine learning-based image analysis, and the integration of spatial biomarker analytics into decision-making processes.
Data Interpretation & Reporting: Providing expert analysis of pathology data, ensuring a strong correlation with clinical outcomes and mechanistic insights.
Cross-Functional Leadership: Engaging with colleagues in Translational Medicine, Bioinformatics, and Clinical Development to integrate candidate biomarkers into Translational Biomarker plans for RAS(ON) inhibitors, aligning with overarching clinical development strategies.
Responsibilities
Scientific Leadership & Execution: Analyzing and interpreting multiplex spatial biomarker datasets to inform translational hypotheses and clinical strategies, while establishing quality control standards for data acquisition and analysis.
Cross-Functional Collaboration: Partnering with Research and Clinical teams to incorporate spatial biomarker findings into translational plans and collaborating with Systems Biology and Information Sciences teams to enhance visualization tools.
External Partnership Management: Acting as the primary scientific liaison to Contract Research Organizations (CROs) for spatial biomarker workflows, reviewing deliverables, troubleshooting issues, and fostering continuous improvement.
Capability Building: Documenting best practices and standard operating procedures (SOPs) for spatial biomarker workflows, while recommending platform upgrades and pilot evaluations.

